Use Code ONLINE20 to Save 20% On Global Market Reports – Gain Access to Trusted Market Data, Growth Indicators, and Industry Analytics
What Is the Current Size and Annual Growth Rate of the Polymyositis Market?
The polymyositis market size has grown strongly in recent years. It will grow from $1.65 billion in 2024 to $1.74 billion in 2025 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to rising access in developing regions, increased use of prednisone, the rising popularity of methotrexate in managing symptoms, growing use of TNF inhibitors, and an increase in the use of antibody testing.
The polymyositis market size is expected to see strong growth in the next few years. It will grow to " $2.21 billion in 2029 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to growth in telemedicine, rise in the use of remote monitoring, increasing use of immunosuppressants, rise in the use of stem cell therapy, and growth in the use of biosimilars. Major trends in the forecast period include the integration of artificial intelligence in drug discovery, advancements in targeted therapies, development of novel immunomodulators, rising research in regenerative medicine, and integration of big data.
Get your free report sample today:
What Are the Primary Factors Driving the Polymyositis Market?
The increasing prevalence of autoimmune diseases is expected to propel the growth of the polymyositis market going forward. Autoimmune diseases refer to medical conditions in which the body's immune system mistakenly attacks its own healthy cells, tissues, or organs, leading to inflammation and damage. The prevalence of autoimmune diseases is increasing as certain genetic variants can lead to an overactive immune response, making individuals more susceptible to mistakenly attacking their own tissues. This genetic susceptibility, combined with environmental triggers such as infections, stress, and lifestyle factors, contributes to the rising incidence of autoimmune conditions. Polymyositis enhances the understanding of autoimmune diseases by demonstrating how immune system dysfunction leads to muscle inflammation, offering insights into underlying mechanisms and potential treatments for related conditions. For instance, in November 2024, according to the Versorgungsatlas.de, a Germany-based organization, in 2022, among 73,241,305 insured individuals, 6,304,340 were diagnosed with at least one autoimmune disease, resulting in a raw prevalence rate of 8.61%. Therefore, the increasing prevalence of autoimmune diseases is driving the Polymyositis market.
How Is the Polymyositis Market Categorized Based on Key Segments?
The polymyositismarket covered in this report is segmented –
1) By Type: Idiopathic Polymyositis; Dermatomyositis; Inclusion Body Myositis; Overlapping Myositis Syndromes
2) By Diagnosis: Physical Examination; Muscle Biopsy; Electromyography (EMG); Blood Tests; Magnetic Resonance Imaging (MRI)
3) By Treatment: Immunosuppressant; Immunoglobulins; Corticosteroids; Alkylating agents; Monoclonal Antibodies
4) By Distribution Channel: Offline; Online
5) By End User: Hospital pharmacy; Online pharmacy; Retail pharmacy
Subsegments:
1) By Idiopathic Polymyositis: Immune-Mediated Polymyositis; Virus-Associated Polymyositis
2) By Dermatomyositis: Classic Dermatomyositis; Amyopathic Dermatomyositis; Juvenile Dermatomyositis
3) By Inclusion Body Myositis: Sporadic Inclusion Body Myositis; Hereditary Inclusion Body Myopathy
4) By Overlapping Myositis Syndromes:Polymyositis with Systemic Lupus Erythematosus (SLE); Polymyositis with Rheumatoid Arthritis (RA); Polymyositis with Systemic Sclerosis; Polymyositis with Mixed Connective Tissue Disease (MCTD)
What Are the Most Prominent Trends Impacting the Polymyositis Market?
Major companies operating in the polymyositis market are focusing on developing innovative therapies such as stem cell therapy to enhance treatment efficacy and slow disease progression. Stem cell therapy involves the use of umbilical cord-derived stem cells for regenerative treatment. These stem cells have strong immunomodulatory and anti-inflammatory properties, making them a promising option for treating autoimmune diseases such as polymyositis. For instance, in December 2024, RESTEM, a US-based clinical-stage biotechnology company, received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for its stem cell program utilizing umbilical cord outer lining stem cells (ULSCs). This program utilizes umbilical cord outer lining stem cells to treat polymyositis and Dermatomyositis by regulating the immune system and reducing muscle inflammation. The therapy has shown promising safety and efficacy in early trials, with potential to decrease steroid dependency.
Who Are the Major Companies Operating in the Polymyositis Market?
Major companies operating in the polymyositis market are Pfizer Inc., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Merck & Co. Inc., C.H. Boehringer Sohn AG & Co. KG, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Fresenius SE & Co. KGaA, UCB S.A., Reliance Life Sciences Private Limited, ARUP Laboratories, Teva Pharmaceuticals USA Inc., Kezar Life Sciences Inc., Argenx SE, Mallinckrodt Pharmaceuticals plc, Mitsubishi Tanabe Pharma Corporation, ViiV Healthcare Limited
Get the detailed polymyositis market report today
Which Region Holds the Largest Share of the Polymyositis Market?
North America was the largest region in the polymyositis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the polymyositis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: The Business Research Company | LinkedIn
Comments
Post a Comment